The global exosomes market size was estimated to be USD 0.374 billion in 2023 and is expected to reach at USD 1.76 billion by 2034 with a CAGR of 15.12% during the forecast period 2024-2034. Advanced applications of exosomes, expansion of both government & non-government initiatives dedicated to exosome research, growing prevalence of chronic disorders such as cancer, increasing research & development activities involving exosomes, rising demand for effective novel therapeutic options for the diagnosis and treatment of the disease, surge in launch of innovative products, and increasing technological advancements in the isolation and analytical techniques for exosomes are some of the key factors boosting the market growth.
Increasing technological advancements in the isolation and analytical techniques for exosomes is predicted to boost the market growth during the forecast period. Exosomes can be modified to transport a wide range of therapeutic payloads, such as short interfering ribonucleic acids (RNAs), antisense oligonucleotides, chemotherapeutic drugs, and immune modulators, allowing precise targeting of these payloads. Exosome vesicle-based liquid biopsy holds the potential for use in diagnosing and assessing the prognosis of patients with cancer and various other diseases. These advancements are anticipated to increase the adoption of exosomes in research applications and stimulate growth within the industry. For instance, in November 2022, Cell Guidance Systems has launched its Instant Exosomes and LipoQ assay products. Instant Exosomes are freeze-dried exosomes, while LipoQ is a lipid quantification assay designed for research purposes.
By product, kits and reagents was the highest revenue-grossing segment in the global exosomes market in 2023 owing to the rising launch of innovative kits & reagents to broaden the applications of exosomes, the proliferation of technologically advanced products is aiding researchers in the exploration & refinement of exosome-based therapeutics & diagnostic applications allowing them to investigate novel biomarkers, and increasing collaborations among key players. For instance, in February 2022, Bio-Techne has entered an exclusive agreement with Thermo Fisher Scientific for the development and commercialization of the ExoTRU kidney transplant rejection test created by Bio-Techne. This liquid biopsy test provides valuable information about allograft health, catering to both clinical and research applications. Additionally, services is predicted to grow at fastest CAGR during the forecast period owing to the end-users are opting to outsource the processes of isolation, characterization, & therapeutic development to reduce turnaround times and numerous industry participants provide exosome services to meet this demand.
By workflow, downstream analysis was the highest revenue-grossing segment in the global exosomes market in 2023 owing to the growing effectiveness & applicability of advanced downstream analysis methods and increasing collaborations within market players. For instance, in January 2023, Sartorius AG has partnered with RoosterBio to enhance downstream purification processes used in the production of exosomes. Additionally, isolation method is predicted to grow at fastest CAGR during the forecast period. The selection of the most suitable exosome isolation method depends on factors such as the type and quantity of the initial material (e.g., urine, cell culture media, plasma, etc.), intended therapeutic application, administration route, equipment accessibility, and desired final product. Common isolation methods encompass ultracentrifugation, immunocapture using beads, precipitation, and filtration, among others. Companies are providing smart isolation platforms that streamline workflows, expedite turnaround times, enhance yield, and preserve exosomes' integrity, contributing to the growth of this segment.
By application, cancer was the highest revenue-grossing segment in the global exosomes market in 2023 owing to the wide array of exosomes applications in cancer, including diagnosis, prognosis, & treatment, growing cancer prevalence, surge in need for early detection of the disease, and increasing launch of advanced platforms. For instance, in August 2022, Creative Biolabs has introduced the innovative Nanosight platform for exosome characterization. This platform is available for use by various research and industrial customers and offers capabilities for size distribution analysis, exosome concentration measurement, and phenotyping evaluation. Additionally, infectious diseases is predicted to grow at fastest CAGR during the forecast period. Exosomes are recognized for their role in the development of numerous infectious diseases. The capacity of extracellular vesicles to transport a diverse range of molecules to distant or nearby sites, facilitating a multitude of biological functions, is a crucial attribute of these vesicles. This transport mechanism holds potential for the creation of therapeutic approaches, including vaccination.
By end-user, pharmaceutical & biotechnology companies was the highest revenue-grossing segment in the global exosomes market in 2023 owing to the growing demand for therapeutics and vaccines based on extracellular vesicles, rising partnerships & collaboration within several pharmaceuticals & biotechnology companies. For instance, in November 2022, Sartorius BIA Separations and Exopharm have formed a partnership with the aim of enhancing the production and commercialization of large-scale therapeutic exosomes. Additionally, academic & research institutes is predicted to grow at fastest CAGR during the forecast period owing to the rising emphasis by various research institutions on leveraging exosomes for the exploration & creation of innovative therapeutics and surge in research activities.
North America region is anticipated for the highest revenue share during the forecast period owing to the increasing government funding for the detection of new biomarkers, growing incidence of chronic disorders, such as cardiovascular diseases & cancer, and rising launch of new products. For instance, in April 2022, Global Stem Cells Group (GSCG) has introduced a new product line featuring novel Lyophilized Exosome Technology. This innovative product range from GSCG comprises anti-aging products designed to rejuvenate cells and tissues within the body. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the growing number of collaborative initiatives involving both public & private sectors, surge in research & development efforts aimed at developing of novel drugs, diagnostic techniques, & treatment approaches, and rising partnerships within market players. For instance, in October 2022, FUJIFILM Diosynth Biotechnologies has established a strategic collaboration with RoosterBio to facilitate the GMP-compliant manufacturing of exosome and cell therapies.
Increasing technological advancements in the isolation and analytical techniques for exosomes is predicted to boost the market growth during the forecast period. Exosomes can be modified to transport a wide range of therapeutic payloads, such as short interfering ribonucleic acids (RNAs), antisense oligonucleotides, chemotherapeutic drugs, and immune modulators, allowing precise targeting of these payloads. Exosome vesicle-based liquid biopsy holds the potential for use in diagnosing and assessing the prognosis of patients with cancer and various other diseases. These advancements are anticipated to increase the adoption of exosomes in research applications and stimulate growth within the industry. For instance, in November 2022, Cell Guidance Systems has launched its Instant Exosomes and LipoQ assay products. Instant Exosomes are freeze-dried exosomes, while LipoQ is a lipid quantification assay designed for research purposes.
By product, kits and reagents was the highest revenue-grossing segment in the global exosomes market in 2023 owing to the rising launch of innovative kits & reagents to broaden the applications of exosomes, the proliferation of technologically advanced products is aiding researchers in the exploration & refinement of exosome-based therapeutics & diagnostic applications allowing them to investigate novel biomarkers, and increasing collaborations among key players. For instance, in February 2022, Bio-Techne has entered an exclusive agreement with Thermo Fisher Scientific for the development and commercialization of the ExoTRU kidney transplant rejection test created by Bio-Techne. This liquid biopsy test provides valuable information about allograft health, catering to both clinical and research applications. Additionally, services is predicted to grow at fastest CAGR during the forecast period owing to the end-users are opting to outsource the processes of isolation, characterization, & therapeutic development to reduce turnaround times and numerous industry participants provide exosome services to meet this demand.
By workflow, downstream analysis was the highest revenue-grossing segment in the global exosomes market in 2023 owing to the growing effectiveness & applicability of advanced downstream analysis methods and increasing collaborations within market players. For instance, in January 2023, Sartorius AG has partnered with RoosterBio to enhance downstream purification processes used in the production of exosomes. Additionally, isolation method is predicted to grow at fastest CAGR during the forecast period. The selection of the most suitable exosome isolation method depends on factors such as the type and quantity of the initial material (e.g., urine, cell culture media, plasma, etc.), intended therapeutic application, administration route, equipment accessibility, and desired final product. Common isolation methods encompass ultracentrifugation, immunocapture using beads, precipitation, and filtration, among others. Companies are providing smart isolation platforms that streamline workflows, expedite turnaround times, enhance yield, and preserve exosomes' integrity, contributing to the growth of this segment.
By application, cancer was the highest revenue-grossing segment in the global exosomes market in 2023 owing to the wide array of exosomes applications in cancer, including diagnosis, prognosis, & treatment, growing cancer prevalence, surge in need for early detection of the disease, and increasing launch of advanced platforms. For instance, in August 2022, Creative Biolabs has introduced the innovative Nanosight platform for exosome characterization. This platform is available for use by various research and industrial customers and offers capabilities for size distribution analysis, exosome concentration measurement, and phenotyping evaluation. Additionally, infectious diseases is predicted to grow at fastest CAGR during the forecast period. Exosomes are recognized for their role in the development of numerous infectious diseases. The capacity of extracellular vesicles to transport a diverse range of molecules to distant or nearby sites, facilitating a multitude of biological functions, is a crucial attribute of these vesicles. This transport mechanism holds potential for the creation of therapeutic approaches, including vaccination.
By end-user, pharmaceutical & biotechnology companies was the highest revenue-grossing segment in the global exosomes market in 2023 owing to the growing demand for therapeutics and vaccines based on extracellular vesicles, rising partnerships & collaboration within several pharmaceuticals & biotechnology companies. For instance, in November 2022, Sartorius BIA Separations and Exopharm have formed a partnership with the aim of enhancing the production and commercialization of large-scale therapeutic exosomes. Additionally, academic & research institutes is predicted to grow at fastest CAGR during the forecast period owing to the rising emphasis by various research institutions on leveraging exosomes for the exploration & creation of innovative therapeutics and surge in research activities.
North America region is anticipated for the highest revenue share during the forecast period owing to the increasing government funding for the detection of new biomarkers, growing incidence of chronic disorders, such as cardiovascular diseases & cancer, and rising launch of new products. For instance, in April 2022, Global Stem Cells Group (GSCG) has introduced a new product line featuring novel Lyophilized Exosome Technology. This innovative product range from GSCG comprises anti-aging products designed to rejuvenate cells and tissues within the body. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the growing number of collaborative initiatives involving both public & private sectors, surge in research & development efforts aimed at developing of novel drugs, diagnostic techniques, & treatment approaches, and rising partnerships within market players. For instance, in October 2022, FUJIFILM Diosynth Biotechnologies has established a strategic collaboration with RoosterBio to facilitate the GMP-compliant manufacturing of exosome and cell therapies.
Segmentation: Exosomes Market Report 2023 - 2034
Exosomes Market Analysis & Forecast by Product 2023 - 2034 (Revenue USD Bn)
- Services
- Instruments
- Kits & Reagents
Exosomes Market Analysis & Forecast by Workflow 2023 - 2034 (Revenue USD Bn)
- Downstream Analysis
- Cell Surface Marker Analysis Using Flow Cytometry
- Proteomic Analysis Using Mass Spectroscopy
- Protein Analysis Using Blotting & ELISA
- RNA Analysis With NGS & PCR
- Others
- Isolation Methods
- Immunocapture On Beads
- Ultracentrifugation
- Precipitation
- Filtration
- Others
Exosomes Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)
- Cardiovascular Diseases
- Cancer
- Infectious Diseases
- Neurodegenerative Diseases
- Others
Exosomes Market Analysis & Forecast by End-user 2023 - 2034 (Revenue USD Bn)
- Academic & Research Institutes
- Pharmaceutical & Biotechnology Companies
- Hospitals & Diagnostics Centers
Exosomes Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Exosomes Market: Product Estimates & Trend Analysis
8. Exosomes Market: Workflow Estimates & Trend Analysis
9. Exosomes Market: Application Estimates & Trend Analysis
10. Exosomes Market: End-user Estimates & Trend Analysis
11. Regional Market Analysis
12. North America Exosomes Market
13. Europe Global Exosomes Market
14. Asia Pacific Global Exosomes Market
15. Latin America Global Exosomes Market
16. MEA Global Exosomes Market
17. Competitor Analysis
18. Company Profiles
Companies Mentioned
- Thermo Fisher Scientific Inc.
- Fujifilm Holdings Corp.
- Hologic Inc.
- Bio-Techne Corp.
- Abcam plc
- Lonza
- Danaher Corp.
- RoosterBio Inc.
- QIAGEN
- Miltenyi Biotec
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | January 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 0.37 Billion |
| Forecasted Market Value ( USD | $ 1.76 Billion |
| Compound Annual Growth Rate | 15.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
